Generation of a novel antibody-antibiotic conjugate as a combination therapy platform to treat melioidosis or plague.
Active Definitive Contract Awarded Last action
- Contract number
- HDTRA124C0008
- Awardee
-
Ministry Of Defence UEI U6LDUQKZ2CS8
- Awarding agency
-
Defense Threat Reduction Agency
Department of Defense
- Obligated
- $5,630,591
Award facts
- Opportunity
-
- HDTRA114S0001 Solicitation number
- Contract value 67% obligated
-
- $5,630,590.98 Current, with exercised options
- $8,415,742.93 Potential, with all options
- Completion date 43% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Great Britain, United Kingdom
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $2,023,998 | |
| Funding Only Action | $1,500,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $778,694 | |
| Funding Only Action | $221,306 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $186,266 | |
| Funding Only Action | $385,696 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $534,631 |
About this award
The Defense Threat Reduction Agency awarded an $8.415 million definitive contract to the Ministry of Defence, operating as Defence Science and Technology Laboratory (DSTL), on June 10, 2024, for generation of a novel antibody-antibiotic conjugate as a combination therapy platform to treat melioidosis and plague.
This is a cost-plus-fixed-fee contract with no set-aside. Place of performance is Great Britain, United Kingdom. The contract runs through December 9, 2029. The originating solicitation describes Thrust 7 research focused on development of the antibody-antibiotic conjugate platform as a medical countermeasure against these biological threats.
Quick answers
Who was awarded contract HDTRA124C0008?
HDTRA124C0008 was awarded to Ministry Of Defence by Defense Threat Reduction Agency (Department of Defense) on June 10, 2024.
How much is contract HDTRA124C0008 worth?
The government has obligated $5,630,591 on HDTRA124C0008. Its potential value, with all options, is $8,415,743.
Was contract HDTRA124C0008 competed?
The extent of competition for HDTRA124C0008 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award